Inogen, Inc - Common Stock (INGN)

Divestiture cash and cost cuts reshape Inogen's path to profit.

Inogen (NASDAQ:INGN) reported lower third-quarter revenue as weaker spending by large European customers offset a return to growth in U.S. sales. The respiratory care company also outlined a $20 million annualized cost-reduction program following the sale of its U.S. oxygen rental business. Revenue

International sales surged 14.8% as new product categories expanded the addressable market.

Inogen (NASDAQ:INGN) reported second-quarter 2026 revenue of $95.1 million, up 3% from a year earlier, as international growth, portable oxygen concentrator demand and contributions from newer products offset continued pressure in its U.S. direct-to-consumer business. The company lowered its full-y

Inogen's Q3 2025 results were mixed, with revenue slightly missing estimates but a narrower-than-expected loss. The stock rose as the company showed progress on its path to profitability.

Needham's Mike Matson upgrades Inogen to Buy, citing turnaround progress, margin gains, and path to EBITDA breakeven by 2025.

Inogen beat Q4 earnings and revenue estimates, citing strong B2B demand. Analysts see potential but flag supply challenges and restructuring risks.

Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!

Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries.

INGN stock results show that Inogen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.27% to 38,867.91 while the NASDAQ fell 0.50% to 15,954.75. The S&P 500 also fell, dropping, 0.18% to 5,068.92.

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.